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To the Editor: In their interesting paper, Ashby et al.1
report significantly elevated levels of serum hepcidin in
patients with chronic kidney disease (CKD). Although
serum ferritin was the main determinant of hepcidin levels,
a significant negative correlation with glomerular filtration
rate (GFR) remained in multivariate regression analysis.
These data thus suggest that in patients with CKD the low
GFR may contribute to higher levels of hepcidin, thus
contributing to the anemia of CKD. Of note, the authors
used a novel immunoassay that measures total hepcidin, not
only that consisting of bioactive hepcidin-25 but also of the
smaller inactive isoform hepcidin-20. We have measured
serum hepcidin levels in patients with CKD using a mass
spectrometry-based assay that quantifies hepcidin-25 and
hepcidin-20 separately.2 Serum hepcidin-25 levels were
elevated in patients with CKD and correlated with
serum ferritin.3 However, in multiple regression analysis
GFR was not a significant independent predictor of
hepcidin-25. In contrast, we observed a significant indepen-
dent negative relation between GFR and both hepcidin-20
and total hepcidin. We therefore conclude that the
conclusion of Ashby et al. may not be applicable to the
biologically active hepcidin-25 isoform. The biological
relevance of the relationship between total hepcidin and
GFR is questionable.
1. Ashby DR, Gale DP, Busbridge M et al. Plasma hepcidin levels are elevated
but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;
75: 976–981.
2. Swinkels DW, Girelli D, Laarakkers C et al. Advances in quantitative
hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE
2008; 3: e2706.
3. Peters HPE, Laarakkers CMM, Swinkels DW et al. Serum hepcidin-25 levels
in patients with chronic kidney disease are independent of glomerular
filtration rate, submitted.
Hilde P.E. Peters1, Coby M.M. Laarakkers2, Jack F.M. Wetzels1
and Dorine W. Swinkels2
1Department of Nephrology, Radboud University Nijmegen Medical
Center, Nijmegen, The Netherlands and 2Department of Clinical
Chemistry, Radboud University Nijmegen Medical Center, Nijmegen,
The Netherlands
Correspondence: Hilde P.E. Peters, Department of Nephrology, Radboud
University Nijmegen Medical Center, PO BOX 9101, Nijmegen 6500 HB,
The Netherlands. E-mail: h.peters@aigumcn.nl
Response to ‘Hepcidin levels in
patients with renal disease’
Kidney International (2009) 76, 680–681; doi:10.1038/ki.2009.240
The presence in the circulation of biologically inactive
fragments of hepcidin-25 is an important issue,
and the ability to distinguish between them might
be an advantage of assays based on mass spectrometry.
Peters et al.1 comment that they also found elevated
circulating hepcidin-25 in chronic kidney disease,
but that only hepcidin-20 was independently correlated
with glomerular filtration rate, and conclude that
our measurements are distorted by the inclusion of
hepcidin-20.
However, the immunoassay we used does not measure
total hepcidin. Hepcidin-20 crossreactivity with this anti-
body is o10%, and as described in Figure 3 of our report,
over 90% of the immunoreactivity in renal failure samples
was due to a single species chromatographically identical
to hepcidin-25.2 We have also completed a method
comparison study in which measurements using this
immunoassay and using a mass spectrometry–based
method3 were in close agreement (R¼ 0.96, n¼ 99,
Figure 1).
We offer three alternative explanations for their failure
to identify glomerular filtration rate as an independent
predictor of hepcidin-25. First, there may be qualitative
differences between the populations studied (for example,
due to comorbidities). A second possibility is a type 1 error
in our study, although the significance of glomerular
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Figure 1 |Agreement between hepcidin-25 measurements by
radioimmunoassay (RIA) and mass spectrometry (MS)
methods (n¼ 99).
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filtration rate as a predictor of hepcidin in our model
makes this unlikely (P¼ 0.017). The third possibility is a
type 2 error in their study, which may, in linear regression,
relate to sample size or the number of predictors—
particularly when, as in this case, the effect may be
relatively weak (b¼0.230 vs 0.745 for ferritin in our
model).
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